Clinical Trials and Research Studies
Phase 2
A Phase 2 Study of REGN2810 a Fully Human Monoclonal Antibody to Programmed Death-1 in Patients with Advanced Basal Cell Carcinoma who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy or were Intolerant of Prior Hedgehog Pathway Inhibitor therapy
Learn MorePhase 1
A Phase 1 b Study of the Selective HDAC Inhibitor Mocetinostat in Combination with Ipilimumab and Nivolumab in Patients with Unresectable Stage III or Stage IV Melanoma
Learn MorePhase 1
A Phase 1 First-in-Human Open Label Dose Escalation Study of MGD009 A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART ) Protein in Patients with Unresectable or Metastatic B7-H3-Expressing Neoplasms and Neoplasms whose Vasculature Expresses
Learn MorePhase 2
A Phase 2 Multicenter Single-arm Study to Assess the Safety Feasibility and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-144) Followed by IL-2 for Treatment of Metastatic Melanoma
Learn More